Navigation Links
BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Date:5/7/2013

RALEIGH, N.C., May 7, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo , President and Chief Executive Officer of BDSI, will present at the Bank of America Merrill Lynch 2013 Health Care Conference.  The presentation is scheduled for Tuesday, May 14, 2013 at 5:00 p.m. Pacific Time (8:00 p.m. Eastern Time), at the Encore at Wynn in Las Vegas, Nevada.

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO )

Dr. Sirgo will focus on the development status, timeline and market opportunity for BUNAVAIL for the management of opioid dependence and will discuss progress made by BDSI and its commercial partner, Endo Health Solutions, with the ongoing Phase 3 clinical program for BEMA Buprenorphine for the treatment of chronic pain.  Additionally, Dr. Sirgo will discuss BDSI's recent licensing of Clonidine Topical Gel for the treatment of painful diabetic neuropathy.

The presentation will be webcast live and can be accessed at www.bdsi.com.  For those who are not available to listen to the live broadcast, a replay of the webcast will be available on the BDSI website.

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction. 

BDSI's pain franchise currently consists of three products, two of which utilize the patented BioErodible MucoAdhesive (BEMA) drug delivery technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it is marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.). 

BDSI's second pain product using the BEMA technology, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is licensed on a worldwide basis to Endo Health Solutions.  BDSI's third pain product in development is Clonidine Topical Gel for the treatment of painful diabetic neuropathy, which was recently licensed from Arcion Therapeutics.

Additionally, BDSI is developing BUNAVAIL, a high dose formulation of buprenorphine in combination with naloxone for the treatment of opioid dependence.  Both BEMA Buprenorphine and BUNAVAIL are in Phase 3 clinical development, and Clonodine Topical Gel is in Phase 2 clinical development. 

BDSI's headquarters is located in Raleigh, North Carolina.  For more information visit www.bdsi.com.

Cautionary Note on Forward-Looking Statements

This press release, the presentation referred to herein, and any statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission and those that relate to the Company's ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy.  Actual results (including, without limitation, the timing for and results of the clinical trials and proposed NDA submissions for, and FDA review of, the Company's products in development) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  The BioDelivery Sciences logo and BUNAVAIL™ are trademarks owned by BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL™ is a trademark owned by Meda Pharma GmbH & Co. KG.  All other trademarks and tradenames are owned by their respective owners.


'/>"/>
SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDelivery Sciences Appoints Thomas W. DAlonzo to Board of Directors
2. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
3. BioDelivery Sciences to Present at the 25th Annual ROTH Conference
4. BioDelivery Sciences to Host Buprenorphine Investor and Analyst Event
5. BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
6. BioDelivery Sciences Announces Completion of BNX Safety Study
7. BioDelivery Sciences Announces $40 Million Registered Financing
8. BioDelivery Sciences to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations
10. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
11. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)...  Bayer announced today that the latest research from ... the 53 rd Annual Meeting of the American ... in Chicago . ... liver and thyroid cancers, as well as lymphomas, and ... trial of copanlisib in patients with relapsed or refractory ...
(Date:5/11/2017)... , May 11, 2017  Thornhill Research ... has been awarded an $8,049,024 USD five-year, firm-fixed-priced, ... through the Canadian Commercial Corporation (CCC) ( ... Anesthesia Systems to administer general anesthesia to patients ... "The US Marine Corps have been ...
(Date:5/10/2017)... May 10, 2017 Radiology has become the ... costs have also spiraled to the number one ranking ... radiology than ever before as the most complete and ... patient with lower back pain an MRI may confirm ... for pain, resulting in entirely different treatment protocols.  In ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... 24, 2017 , ... Accordant Technology, a trusted IT solutions ... an analytics-first approach, layered with machine learning, that provides real-time visibility into the ... cloud to the edge. Through the new partnership, customers get the real-time situational ...
(Date:5/24/2017)... ... May 24, 2017 , ... Fiberstar, Inc., ... the food and beverage industry offers Citri-Fi®, a natural citrus fiber, to improve ... decision process. As a result, labels need to deliver simple, transparent and clear ...
(Date:5/23/2017)... , ... May 23, 2017 , ... Allegheny Health ... open The Alexis Joy D’Achille Center for Women’s Behavioral Health at West Penn ... in western Pennsylvania for women suffering from pregnancy-related depression. Construction of the Center ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... body for exercise professionals, is pleased to announce the organization’s Certified Strength Coach ... The NCSF Certified Strength Coach (CSC) program validates the competency of qualified candidates ...
(Date:5/23/2017)... York (PRWEB) , ... May 23, 2017 , ... ... LifeLabs, a leading equipment provider in the modern ART laboratory, to provide hands-on ... in Ft. Lauderdale, Florida. , NextGen LifeLabs, a MedTech Group Purchasing vendor ...
Breaking Medicine News(10 mins):